Silymarin is a hepatoprotective agent, having poor water solubility and oral absorption of
about 23-47%, leading to low bioavailability of the drug. The aim of the present study is to
improve the solubility and dissolution rate and in turn the hepatoprotective activity of the
drug, by formulating its inclusion complex with beta (β)-cyclodextrin, using different methods.
The phase solubility analysis indicates the formation of 1: 1 molar inclusion complex of the
drug with beta cyclodextrin. Apparent stability constant for Silymarin (K c) was 722 K-1 with β …